News und Analysen
What's Causing Align Technology's Shares to Soar 14% Today
After reporting third-quarter financial results that beat industry watchers expectations, shares in Align Technology (NASDAQ: ALGN) are surging 14.1% higher at 11:30 a.m. EDT.Years of double-digit....
What's Causing Align Technology's Shares to Soar 14% Today
After reporting third-quarter financial results that beat industry watchers expectations, shares in Align Technology (NASDAQ: ALGN) are surging 14.1% higher at 11:30 a.m. EDT.Years of double-digit....
Cerner Corporation Unimpressive in 3rd Quarter, but Expects Better Days Ahead
Cerner Corporation (NASDAQ: CERN) started off 2017 with a bang, posting strong revenue and earnings growth in the first quarter. Things slowed down a bit in the second quarter, with the healthcare....
Cerner Corporation Unimpressive in 3rd Quarter, but Expects Better Days Ahead
Cerner Corporation (NASDAQ: CERN) started off 2017 with a bang, posting strong revenue and earnings growth in the first quarter. Things slowed down a bit in the second quarter, with the healthcare....
3 Key Things to Watch in Pfizer's Q3 Results
There wasn't much to get excited about the last time Pfizer (NYSE: PFE) reported its quarterly results. While the big pharma company beat analysts' consensus earnings estimate, it also posted a 2%....
3 Key Things to Watch in Pfizer's Q3 Results
There wasn't much to get excited about the last time Pfizer (NYSE: PFE) reported its quarterly results. While the big pharma company beat analysts' consensus earnings estimate, it also posted a 2%....
Stop Panicking About Celgene
Judging by the market reaction to Celgene's (NASDAQ: CELG) third-quarter results, you'd think one of the Four Horsemen of the Apocalypse just rode down Wall Street. Or maybe two of them....
Align Technology Inc.'s 2017 Is Lining Up Nicely With Another Record Quarter
Align Technology (NASDAQ: ALGN) posted record-high revenue when it announced its first-quarter results earlier this year. The medical-device company, best known for its Invisalign clear aligners,....
Align Technology Inc.'s 2017 Is Lining Up Nicely With Another Record Quarter
Align Technology (NASDAQ: ALGN) posted record-high revenue when it announced its first-quarter results earlier this year. The medical-device company, best known for its Invisalign clear aligners,....
Align Technology Inc.'s 2017 Is Lining Up Nicely With Another Record Quarter
Align Technology (NASDAQ: ALGN) posted record-high revenue when it announced its first-quarter results earlier this year. The medical-device company, best known for its Invisalign clear aligners,....
Gilead Sciences Inc. Still Singing the HCV Blues in the 3rd Quarter
Surprisingly strong hepatitis C virus (HCV) sales helped Gilead Sciences (NASDAQ: GILD) enjoy better-than-expected results when the big biotech provided its second-quarter update in July. But that....
Gilead Sciences Inc. Still Singing the HCV Blues in the 3rd Quarter
Surprisingly strong hepatitis C virus (HCV) sales helped Gilead Sciences (NASDAQ: GILD) enjoy better-than-expected results when the big biotech provided its second-quarter update in July. But that....
Gilead Sciences Inc. Still Singing the HCV Blues in the 3rd Quarter
Surprisingly strong hepatitis C virus (HCV) sales helped Gilead Sciences (NASDAQ: GILD) enjoy better-than-expected results when the big biotech provided its second-quarter update in July. But that....
Was Celgene’s Third Quarter Really Crash-Worthy?
On the heels of reporting a disappointing late-stage trial failure, Celgene Corp. (NASDAQ: CELG) issued a poor third-quarter financial report that's stoking investors' fears. Has the biotech lost....
The Clear Reason Alkermes Plc's Shares Jumped by as Much as 12%
Shares of Alkermes (NASDAQ: ALKS), an Irish-based commercial-stage drug developer with a focus on central nervous system medicines, jumped by as much as 12% during Thursday's trading session and....
The Double Whammy That Sent Marijuana Stock Insys Therapeutics Crashing as Much as 30%
Shares of Insys Therapeutics (NASDAQ: INSY), a small-cap biotech with a focus on pain management, plunged as much as 30% on Wednesday after receiving a double whammy. One whammy was the arrest of....
Oh Baby! Natus Medical Inc. Beats and Raises Guidance
Natus Medical (NASDAQ: BABY) continues its turnaround, hitting its third-quarter revenue guidance and beating its own expectations for adjusted earnings, which were forecast to be in the range of....
Abiomed, Inc's Revenue and Profits Soar Yet Again
Abiomed (NASDAQ: ABMD), a medical-device maker focused on minimally invasive heart pumps, reported its fiscal second-quarter earnings on Thursday, Oct. 26. The company once again reported strong....
Abiomed, Inc's Revenue and Profits Soar Yet Again
Abiomed (NASDAQ: ABMD), a medical-device maker focused on minimally invasive heart pumps, reported its fiscal second-quarter earnings on Thursday, Oct. 26. The company once again reported strong....
Alkermes Reports Mixed Results, Updates Guidance
Alkermes (NASDAQ: ALKS), a commercial-stage biopharmaceutical company focused on diseases of the central nervous system, reported its third-quarter earnings results on Thursday, Oct. 26. While....
Should You Be Worried After Bristol-Myers Squibb's Q3 Results?
It's been an up-and-down kind of year for Bristol-Myers Squibb (NYSE: BMY). Early in 2017, investors were concerned after the company opted not to pursue accelerated approval for a combination of....
3 Dividend Stocks Perfect for Retirement
Retirement is a time to shift one's investment portfolio to a more defensive posture. If this can be done while generating income via dividend payouts, so much the better. We asked three of our....
3 Dividend Stocks Perfect for Retirement
Retirement is a time to shift one's investment portfolio to a more defensive posture. If this can be done while generating income via dividend payouts, so much the better. We asked three of our....
Why Celgene Corporation Tumbled Today
Celgene (NASDAQ: CELG) is down 18.2% at 12:11 p.m. Thursday after releasing third-quarter earnings. It wasn't so much third-quarter revenue, which was up 10% year over year, or the adjusted....
Here's Why Idera Pharmaceuticals Plunged as Much as 35% Today
Shares of pre-revenue biopharma Idera Pharmaceuticals (NASDAQ: IDRA) sank as much as 35% this morning after the company announced the pricing of a major public stock offering. The company will....